{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:29:02Z","timestamp":1790814542703,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1136\/ijgc-2023-004308","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T10:40:48Z","timestamp":1681728048000},"page":"1247-1252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct02442531","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03712423","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03742713","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03742713","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-6346","authenticated-orcid":false,"given":"Ingrid","family":"Boere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Hanssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Jalving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gennigens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella","family":"Ottevanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yes J.","family":"van de Wouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristianne J.F.","family":"Rijcken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-3539","authenticated-orcid":false,"given":"Jonathan","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004308_bb0010","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer Intergroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0015","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0025","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ijgc-00009577-200503000-00004","article-title":"Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance","volume":"15","author":"See","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004308_bb0035","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","article-title":"European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion","volume":"12","author":"Eisenhauer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0040","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0045","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0050","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0055","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1200\/JCO.1994.12.11.2301","article-title":"Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer","volume":"12","author":"Francis","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0060","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0959-8049(02)00242-3","article-title":"Dose-dense cisplatin\/paclitaxel","volume":"38","author":"de Jongh","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004308_bb0065","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.ejca.2012.11.027","article-title":"Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer","volume":"49","author":"van der Burg","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004308_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ygyno.2012.10.004","article-title":"The \u201cLeuven\u201d paclitaxel\/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study","volume":"128","author":"Cadron","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0075","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjc.6604914","article-title":"Extended weekly dose-dense paclitaxel\/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer","volume":"100","author":"Sharma","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004308_bb0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","article-title":"Tumor evolution and chemoresistance in ovarian cancer","volume":"2","author":"Kim","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0085","doi-asserted-by":"crossref","first-page":"100777","DOI":"10.1016\/j.drup.2021.100777","article-title":"Novel nanomedicines to overcome cancer multidrug resistance","volume":"58","author":"Su","year":"2021","journal-title":"Drug Resist Updat"},{"key":"10.1136\/ijgc-2023-004308_bb0090","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.2147\/IJN.S272529","article-title":"Recent clinical developments of nanomediated drug delivery systems of taxanes for the treatment of cancer","volume":"Volume 15","author":"van Eerden","year":"2020","journal-title":"Int J Nanomedicine"},{"key":"10.1136\/ijgc-2023-004308_bb0095","doi-asserted-by":"crossref","first-page":"114613","DOI":"10.1016\/j.addr.2022.114613","article-title":"Design, development and clinical translation of Cripec\u00ae-based core-crosslinked polymeric micelles","volume":"191","author":"Rijcken","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1136\/ijgc-2023-004308_bb0100","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-20-0008","article-title":"Intratumoral comparison of nanoparticle entrapped docetaxel (CPC634) with conventional docetaxel in patients with solid tumors","volume":"26","author":"Atrafi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004308_bb0105","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2020.06.020","article-title":"A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours","volume":"325","author":"Atrafi","year":"2020","journal-title":"J Control Release"},{"key":"10.1136\/ijgc-2023-004308_bb0110","first-page":"305","article-title":"Pharmacokinetics and metabolism of Taxotere (docetaxel)","volume":"17","author":"Bruno","year":"1993","journal-title":"Cancer Surv"},{"key":"10.1136\/ijgc-2023-004308_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153741","article-title":"Docetaxel skin exposure and micronucleation contributes to skin toxicity caused by CPC634","volume":"13","author":"Atrafi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-004308_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202201043","article-title":"PET-CT imaging of polymeric nanoparticle tumor accumulation in patients","volume":"34","author":"Miedema","year":"2022","journal-title":"Adv Mater"},{"key":"10.1136\/ijgc-2023-004308_bb0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004308_bb0130","author":"US Department of Health and Human Services","year":"2017","journal-title":"NCI common terminology criteria for adverse events (CTCAE) v5.0"},{"key":"10.1136\/ijgc-2023-004308_bb0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and Ca 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004308_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113323","article-title":"Mechanisms of taxane resistance","volume":"12","author":"Maloney","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-004308_bb0145","doi-asserted-by":"crossref","first-page":"759146","DOI":"10.3389\/fphar.2021.759146","article-title":"Tissue type differences in ABCB1 expression and paclitaxel tissue pharmacokinetics in patients with esophageal cancer","volume":"12","author":"van Eerden","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1136\/ijgc-2023-004308_bb0150","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ctrv.2015.04.012","article-title":"Inter-patient variability in docetaxel pharmacokinetics: a review","volume":"41","author":"Nieuweboer","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/ijgc-2023-004308_bb0155","first-page":"82","article-title":"Resistance to anti-tubulin agents: from vinca alkaloids to epothilones","volume":"2","author":"Krause","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1136\/ijgc-2023-004308_bb0160","doi-asserted-by":"crossref","first-page":"100742","DOI":"10.1016\/j.drup.2020.100742","article-title":"Taxanes in cancer treatment: activity, chemoresistance and its overcoming","volume":"54","author":"Mosca","year":"2021","journal-title":"Drug Resist Updat"},{"key":"10.1136\/ijgc-2023-004308_bb0165","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.1995.13.1.70","article-title":"Value of P-glycoprotein, glutathione S-transferase pi, c-erbb-2, and p53 as prognostic factors in ovarian carcinomas","volume":"13","author":"van der Zee","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004308_bb0170","first-page":"1037","article-title":"Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion","volume":"53","author":"Extra","year":"1993","journal-title":"Cancer Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24016591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24016591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:28:50Z","timestamp":1753234130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24016591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1048891X24016591"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004308","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}